跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
HIZENTRA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
HIZENTRA
Authorized
STANDARD
HIZENTRA
csl behring canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
841bb27a27466c44
Company
csl behring canada inc
Type
Standard
Approval Details
Approval Id
841bb27a27466c44
Drug Approval Canada Name
HIZENTRA
Product Name
HIZENTRA
Status
Marketed
Status Date
2024-02-15
Original Market Date
2024-02-15
Din
02535424
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D
Ahfs
80:04.00
Atc Original
J06BA01 IMMUNOGLOBULINS, NORMAL HUMAN, FOR EXTRAVASC. ADM
Atc Name
j 06 ba 01
Aig Number
0106267011
Company Name
csl behring canada inc
Company Address
350, 55 Metcalfe Street, Ottawa, Ontario, Canada, K1P 6L5
Active Ingredients
IMMUNOGLOBULIN (HUMAN)
200 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
841bb27a27466c44
Type
Standard
Back to Health Canada Approvals